Wall Street Reporter Publishes Comments From Pharmadrug Inc (OTCMKTS: LMLLF), Biodesix Inc (NASDAQ: BDSX), Nova Mentis Life Sciences (OTCMKTS: NMLSF), and Polarityte Inc (NASDAQ: PTE)

Wall Street recently published comments from the company CEOs of Pharmadrug Inc (OTCMKTS: LMLLF), Biodesix Inc (NASDAQ: BDSX), Nova Mentis Life Sciences (OTCMKTS: NMLSF), and Polarityte Inc (NASDAQ: PTE). This news comes with the pharmaceutical industry growing past $1.3 trillion globally.

Comments CEOs have made

According to the Wall Street Reporter, the CMO of Nova Mentis, Dr Marvin Hausman, the company’s latest project has the potential to become a groundbreaking therapy for Autism and other Neurological diseases.

Dr Hausman has worked in the pharmaceutical markets for years and thus has experience working with the U.S Food and Drug Administration (FDA) to ensure the approval of therapies. For this reason, the CMO is the right person to lead the drug towards approval, marketing, and earning revenue.

Gary Pestano, Biodesix CEO, on the other hand, announced that it had published a peer-reviewed study on its lung cancer tests. Pestano believes that the publication indicates the validity of the company’s project.

Dan Cohen, Pharmadrug’s CEO, was also covered in the Wall Street Reporter. The publication detailed how the executive plans to expand the company’s reach in the natural-based drug market.

The move would enable the company to benefit significantly in glaucoma, anti-viral, and cancer indications, which are markets worth billions. Furthermore, the company is working on starting clinical trials for three of its drugs.

Richard Hague, the CEO of PolarityTE, has also stated that it had received a patent allowance from the USPTO. This is the first allowance the company has from the country. Hague explains this move would help the company protect its regenerative tissue technology and expand its patent portfolio

Lixte Biotechnology Holdings (NASDAQ: LIXTW) releases new data on  LB-100

Meanwhile, Lixte Biotechnology Holdings (NASDAQ: LIXTW) released new information on its LB-100 therapy. This drug is for treating cancer. Professor René Bernards, who works for the company, presented the data at the Annual Meeting of the American Association for Cancer Research, New Orleans.

At the meeting, Bernards talked about his out-of-the-box methods for treating cancer. Moreover, the CEO and Founder of Lixte, Dr John S. Kovach, expressed the company’s excitement to partner with the professor. He adds that Professor Bernards’ expertise enables the company to leverage LB-100’s benefits fully.